A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

Introduction: Understanding drug exposure at disease target sites is pivotal to profiling new drug candidates in terms of tolerability and efficacy. Such quantification is particularly tedious for anti-tuberculosis (TB) compounds as the heterogeneous pulmonary microenvironment due to the infection m...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Federico Reali, Anna Fochesato, Chanchala Kaddi, Roberto Visintainer, Shayne Watson, Micha Levi, Véronique Dartois, Karim Azer, Luca Marchetti
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Subjects:	minimal PBPK model mPBPK antituberculosis agents modeling simulation tuberculosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1272091/full